Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
Primary result · LSM change from baseline in UAResult — go to the resultPlacebo-adjusted LSM change −0.26 mg/dL 95% CI −0.36 to −0.16Authors' conclusion
Ertugliflozin was generally associated with lowering UA overall and across subgroups compared with placebo, and numerically reduced rates of gout-related outcome events.
Study context
- Population
- Participants with T2D and atherosclerotic CVD
- Comparison
- Pooled ertugliflozin vs placebo
- Primary endpoint
- Mean serum uric acid (UA) over time
- Follow-up
- 260 weeks
Primary result
LSM change from baseline in UA · Week 260
Placebo-adjusted least squares mean (LSM) change
−0.26 mg/dL
95% CI −0.36 to −0.16
Change by group
Placebo
0.07
LSM change · 95% CI −0.02–0.15 · mg/dL
Ertugliflozin
−0.19
LSM change · 95% CI −0.25–-0.13 · mg/dL
Ertugliflozinvs Placebo
placebo-adjusted LSM change −0.26 mg/dL (95% CI −0.36 to −0.16)
As reported in the abstract
Further findings
Baseline mean UA
| Outcome | Ertugliflozin | Placebo | HR (95% CI) | |
|---|---|---|---|---|
| Composite of gout onset or initiation of anti-gout medication | 2.6% | 3.3% | 0.76 (0.580–1.002) | |
| 0.512Hazard ratio (log scale) |
Uric acid (UA) by baseline UA quintile
- Ertugliflozin associated with reductions in UA across baseline UA quintiles vs placebo
Original publication
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. Diabetes Obes Metab. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →